Latest Press Releases

50% Commission Offering for Initial Distributors. Amnio-Maxx™ will be used to treat various conditions in orthopedics and sports medicine.

This Press Release updates an error in the sub headline
Strategic Partnership: Royal Biologics and Coldplasmatech Revolutionize Complex Wound Care
Strategic Partnership: RoStrategic Partnership: Royal Biologics and Coldplasmatech Revolutionize Complex Wound Careyal Biologics and Coldplasmatech Revolutionize Complex Wound Care


BIOINCYTE™ is a Next-Generation Autologous Fibrin and Platelet System



Royal Biologics' Cryo-Cord™, Amnio-Maxx™, Amnio-Maxx™ Lite and Derm-Maxx™ Receive High-Tier Reimbursement in the Hospital Outpatient Departments and Reimbursement in the Physician Office to Treat Chronic Non-Healing Wounds

The acquisition of the FIBRINET system adds new novel technology to Royal Biologics' growing portfolio of Autologous Live Cell solutions